All News
Biologics Prevent AA amyloidosis progression to ESRD
One of the most serious complications of rheumat0logic and autoimmune diseases can be prevented with biologic drugs, a single-center chart review suggested, and some such products may be more effective than others.
Read ArticleUpdated EULAR Recommendations on the Treatment of Systemic Sclerosis
Medscape has published an overview to the 2024 updated recommendations for the treatment of systemic sclerosis (SSc) presented in Vienna at EULAR 2024 by Professor Francesco Del Galdo, MD, PhD on behalf of a 27 member task force.
Read ArticleEfficacy of Biologics in Patients with Chronic KIdney Disease
A retrospective cohort study of biological disease-modifying antirheumatic drugs (bDMARDs) persistence in rheumatoid arthritis (RA) patients with chronic kidney disease (CKD), shows the 3 year survicval to be under 50% but that all studied biologics were nearly equivalent
PMR - a Risk Factor for Recalcitrant Giant Cell Arteritis?
Despite the clinical similarities and treatment differences between giant cell arteritis (GCA polymyalgia rheumatica (PMR), confusion exists regarding the impact of overlapping disorders.
Future Big BiTEs (6.28.2024)
Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com.
Read Article![](https://pbs.twimg.com/media/GQCXIKkXkAIaz-G.jpg)
![](https://pbs.twimg.com/media/GQCXIKkXkAIaz-G.jpg)
EULAR 2024 – Day 2 Report (A Difficult RA Day)
Day 2 at EULAR 2024 was a big poster day for many with several good sessions and oral presentations on Preventing RA, new vasculitis therapies and a session devoted to the 50th anniversary of the Moll & Wright Criteria.
Read Article![](https://pbs.twimg.com/profile_images/1489576716322447363/HmrVJtAH_normal.jpg)
Mrinalini Dey DrMiniDey ( View Tweet)
EULAR 2024: New drugs for RA?
Several abstracts are presenting new compounds, targeting either RA well-known inflammatory pathways or offering new mechanisms of action or therapeutic sequences; these are summarized below.
Read Article![](https://pbs.twimg.com/profile_images/1702756729/image_normal.jpg)
Peter Nash drpnash ( View Tweet)
Pharmacologic Efficacy in Still's Disease
A systematic review of the effectiveness and safety of pharmacological treatments for adult-onset Still’s disease (AOSD) supports the use of either IL-1 or IL-6 inhibitors.
![](https://abs.twimg.com/sticky/default_profile_images/default_profile_normal.png)
chaim putterman ChaimPutterman ( View Tweet)
Window of Opportunity in Psoriatic Arthritis
A Dutch Early Psoriatic Arthritis cohort study shows that psoriatic arthritis (PsA) patients treated early (referred and diagnosed within in less than 12 weeks) had the best clinical outcomes.
Naysayers & Disrupters (3.22.2024)
Dr. Jack Cush reviews the news and journal reports from the past week - including a few contrary reports on infection, seropositivity and plasmapheresis.
Read ArticleIdes of March (3.15.2024)
Dr. Jack Cush has advice for Caesar and the superstitious, and covers pregnancy, platelets, dialysis and vaccinations in Lupus.
Read ArticleUS Trends in RA DMARD Use 2017-2021
A trend analysis of DMARDs shows that only half of rheumatoid arthritis (RA) patients are taking DMARDs, and that the COVID-19 pandemic substantially affected DMARD use. Despite numerous DMARD advances and evolving treatment guidelines since 1990, older therapies are still commonly used and the latest agents make up a small percentage of overall DMARD use.
Read ArticleJAMA Review of DMARD Use in Rheumatoid Arthritis
JAMA has reviewed the "2022 EULAR Recommendations for the Management of Rheumatoid Arthritis With Synthetic and Biological Disease-Modifying Antirheumatic Drugs".
Read ArticleEffective Treatments for Still's Disease
A systematic review of pharmacological treatments for adult-onset Still disease (AOSD) supports the efficacy of tocilizumab (TCZ), anakinra (ANK), and canakinumab (CNK).
Read ArticleDepression and RA (3.8.2024)
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week.
Read Article